AMPEL BioSolutions has developed CovGENE, a new genomic test, that can detect and predict the severity of Covid-19 in patients.

The new blood test will help determine the necessary treatments and medicines to reduce the chances of hospitalisation.   

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company stated that the test has been validated by a longitudinal study, which was conducted in collaboration with physicians in the Pulmonary and Critical Care Medicine division of the University of Virginia (UVA) Medical Center in the US.

CovGENE showed remarkable precision, with an accuracy of more than 90%, when analysing patients admitted to the UVA Intensive Care Unit.

The test is administered by simply drawing blood from a Covid-19 patient and quickly determines whether the patient will have a mild, moderate or severe outcome.

AMPEL chief medical officer, CEO and co-founder Dr Peter Lipsky said: “This unique collaboration with our colleagues from the University of Virginia has provided an easy and novel means to assess an individual patient’s response to the SARS-CoV-2 virus and predict the clinical outcome.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Now that this unique approach has been validated, we look forward to its rapid development as a precision medicine tool that can improve the outcome of patients with Covid-19 and reduce the number of hospitalisations, especially the most vulnerable.”

At present, the company is working to collaborate with a diagnostic testing company to make CovGENE available to the public.

Additionally, AMPEL claims that the blood test can predict long COVID, an elusive diagnosis that the medical community is still trying to completely understand.

Through this simple blood test, the company’s new approach is expected to expedite the means of providing effective treatments.